Adaptimmune Announces Upcoming Data Presentation at the 2015 Annual Meeting of the Society of Immunotherapy for Cancer (SITC)

PHILADELPHIA and OXFORD, United Kingdom, Oct. 30, 2015 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a clinical stage biopharmaceutical company focused on the use of T-cell therapy to treat cancer, today announced that it will present new data from trials of its NY-ESO affinity enhanced T-cell therapy in patients with synovial sarcoma and myeloma, as well as data from preclinical safety assessments of its affinity enhanced T-cell therapy directed at MAGE A-10, at the 2015 Annual Meeting of the Society of Immunotherapy for Cancer (SITC). SITC is the world’s leading member-driven organization specifically dedicated to professionals working in the field of cancer immunology and immunotherapy.  The meeting will take place at the McCormick Place exhibition center in National Harbor, MD on November 4 through 8, 2015.

Adaptimmune’s poster presentations will take place on November 6, 2015 in the Prince George’s Exhibition Hall from 12:45 to 2:00 pm and are as follows:

Friday November 6, 2015
Poster Presentations
Presentation Time: 12:45-2:00 pm
Location: Prince George's Exhibition Hall

Track Name: Clinical Trials in Progress
Abstract number: 112286
Title: “Optimizing engineered TCR T-cell therapy for synovial sarcoma”
Sandra D’Angelo, M.D., Assistant Attending, Sarcoma Medical Oncology / Immunotherapeutics Core at Memorial Sloan-Kettering Cancer Center will provide additional data from the Company’s NY-ESO-1 synovial sarcoma study.  Updates will include data on the expanded study group, longer follow-up and time-to-event, as well as updated correlative and safety data, and characterization of the product pre and post infusion.

Track Name: Mechanisms and Responses to Immune Therapy
Abstract number: 112346
Title: “Deep phenotypic characterization of NY-ESO TCR engineered T cells and tumor in patients with advanced myeloma”
Presenter: Eduardo Davila, Ph.D., Associate Professor of Microbiology and Immunology at the University of Maryland School of Medicine, Program Leader for Tumor Immunology and Immunotherapy Research Program at the Greenebaum Cancer Center at the University of Maryland will present follow-up data from the recently published Nature Medicine paper, including details on NY-ESO-1 T-cell phenotyping and functional data, as well as clinical and basic correlative data in myeloma patients.

Track Name: Adoptive Immunotherapy
Abstract number: 112244
Title: “Preclinical safety testing of an affinity-optimized MAGE-A10 T cell receptor for adoptive T cell therapy”
Presenter:  Andrew Gerry, Ph.D., Director of Preclinical Research, Adaptimmune Therapeutics will provide a summary of the preclinical safety testing of the Company’s next affinity optimized TCR entering clinical studies in 2015, an affinity-enhanced T-cell therapy targeting MAGE-A10 in patients with non-small cell lung cancer.

Adaptimmune’s affinity enhanced T-cell candidates are novel cancer immunotherapies that have been engineered to target and destroy cancer cells by strengthening a patient’s natural T-cell response. T-cells are a type of white blood cell that play a central role in a person’s immune response. Adaptimmune’s goal is to harness the power of the T-cell and, through its multiple therapeutic candidate, significantly impact cancer treatment and clinical outcomes of patients with multiple solid and hematologic cancers.

About Adaptimmune
Adaptimmune is a clinical stage biopharmaceutical company focused on novel cancer immunotherapy products based on its T-cell receptor (TCR) platform.  Established in 2008, the Company aims to utilize the body’s own machinery – the T-cell – to target and destroy cancer cells by using engineered, increased affinity TCRs as a means of strengthening natural patient T-cell responses. Adaptimmune’s lead program is an affinity enhanced T-cell therapy targeting the NY-ESO cancer antigen. Its NY-ESO TCR affinity enhanced T-cell therapy has demonstrated signs of efficacy and tolerability in Phase 1/2 trials in solid tumors and in hematologic cancer types, including synovial sarcoma and multiple myeloma. As of June 30, 2015, 85 patients had been treated with Adaptimmune’s NY-ESO affinity enhanced T-cell therapy: 47 under Adaptimmune’s IND, and 38 under a National Cancer Institute IND. In June 2014, Adaptimmune announced that it had entered into a strategic collaboration and licensing agreement with GlaxoSmithKline (GSK) for the development and commercialization of the NY-ESO TCR program in partnership with GSK.  In addition, Adaptimmune has a number of proprietary programs and its next affinity enhanced T-cell therapy, directed at MAGE A-10, is scheduled to enter the clinic in 2015. The Company has identified over 30 intracellular target peptides preferentially expressed in cancer cells and is currently progressing 12 through unpartnered research programs. Adaptimmune has over 190 employees and is located in Oxfordshire, U.K. and Philadelphia, USA. For more information:  http://www.adaptimmune.com

Forward-Looking Statements
This press release contains “forward-looking statements,” as that term is defined under the Private Securities Litigation Reform Act of 1995 (PSLRA), which statements may be identified by words such as “believe,” “may”, “will,” “estimate,” “continue,” “anticipate,” “intend,” “expect” and other words of similar meaning.  These forward-looking statements involve certain risks and uncertainties. Such risks and uncertainties could cause our actual results to differ materially from those indicated by such forward-looking statements, and include, without limitation: the success, cost and timing of our product development activities and clinical trials; our ability to submit an IND and successfully advance our technology platform to improve the safety and effectiveness of our existing TCR therapeutic candidates; the rate and degree of market acceptance of T-cell therapy generally and of our TCR therapeutic candidates; government regulation and approval, including, but not limited to, the expected regulatory approval timelines for TCR therapeutic candidates; and our ability to protect our proprietary technology and enforce our intellectual property rights; amongst others. For a further description of the risks and uncertainties that could cause our actual results to differ materially from those expressed in these forward-looking statements, as well as risks relating to our business in general, we refer you to our  Annual Report on Form 20-F filed with the Securities and Exchange Commission on  October 13, 2015. We urge you to consider these factors carefully in evaluating the forward-looking statements herein and are cautioned not to place undue reliance on such forward-looking statements, which are qualified in their entirety by this cautionary statement. The forward-looking statements contained in this press release speak only as of the date the statements were made and we do not undertake any obligation to update such forward-looking statements to reflect subsequent events or circumstances.  We intend that all forward-looking statements be subject to the safe-harbor provisions of the PSLRA.

Adaptimmune Contacts

Will Roberts
Vice President, Investor Relations
T:  (215) 966-6264 
E: will.roberts@adaptimmune.com

Margaret Henry
Head of PR
T: +44 (0)1235 430036
Mob: +44 (0)7710 304249
E: margaret.henry@adaptimmune.com

Released October 30, 2015